Want to see ADIL full AI Analyst Report?
ADIL Stock Chart & Stats
$5.94
$0.10(3.73%)
At close: 4:00 PM EDT
$5.94
$0.10(3.73%)
Day’s Range― - ―
52-Week Range$1.31 - $10.56
Previous CloseN/A
Volume38.05K
Average Volume (3M)42.90K
Market Cap
$10.24M
Enterprise Value$45.46M
Total Cash (Recent Filing)$28.71M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 18, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.53
Shares Outstanding2,625,890
10 Day Avg. Volume30,441
30 Day Avg. Volume42,903
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap4.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-322.44K
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
$11.00Price Target Upside85.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal Debt BurdenEssentially no debt reduces refinancing exposure and interest-rate pressure, preserving more flexibility for clinical development and corporate priorities. This is a durable balance-sheet advantage, although it does not offset the company’s broader capital needs and negative equity position.
Biomarker-focused PipelineA precision-medicine approach may improve the ability to identify responsive patients and differentiate AD04 within addiction treatment. If clinical results validate the biomarker strategy, segmentation could support more efficient development and a clearer commercialization proposition.
Nasdaq Compliance RemediationThe warrant amendments directly address an accounting-driven equity shortfall and are intended to support Nasdaq compliance and planned capital-structure actions. Successful implementation could reduce listing uncertainty and improve the company’s ability to execute financing or strategic plans.
Bears Say
Pre-revenue Development ProfileThe company remains dependent on clinical and regulatory progress because it has no reported commercial revenue. The sharp increase in losses raises execution risk and means future value depends heavily on successful development, approval, and eventual commercialization of its pipeline.
Cash Burn And Negative EquityPersistent cash burn shows that operations are not self-funding and may require continued external capital. Deeply negative equity further limits financial resilience, potentially constraining investment in development programs and increasing dependence on financing or transaction outcomes.
Nasdaq Listing UncertaintyRepeated delays tied to Nasdaq approval indicate that listing compliance remains an unresolved corporate risk rather than a completed remediation. A failure to satisfy requirements could disrupt capital-markets activity, reduce trading access, and complicate execution of planned corporate actions.
Adial Pharmaceuticals News
ADIL FAQ
What was Adial Pharmaceuticals Inc’s price range in the past 12 months?
Adial Pharmaceuticals Inc lowest stock price was $1.31 and its highest was $10.56 in the past 12 months.
What is Adial Pharmaceuticals Inc’s market cap?
Adial Pharmaceuticals Inc’s market cap is $10.24M.
When is Adial Pharmaceuticals Inc’s upcoming earnings report date?
Adial Pharmaceuticals Inc’s upcoming earnings report date is Nov 18, 2026 which is in 38 days.
How were Adial Pharmaceuticals Inc’s earnings last quarter?
Adial Pharmaceuticals Inc released its earnings results on Aug 17, 2026. The company reported -$11.25 earnings per share for the quarter, missing the consensus estimate of -$1.032 by -$10.218.
Is Adial Pharmaceuticals Inc overvalued?
According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Undervalued.
Does Adial Pharmaceuticals Inc pay dividends?
Adial Pharmaceuticals Inc does not currently pay dividends.
What is Adial Pharmaceuticals Inc’s EPS estimate?
Adial Pharmaceuticals Inc’s EPS estimate is -0.18.
How many shares outstanding does Adial Pharmaceuticals Inc have?
Adial Pharmaceuticals Inc has 2,625,890 shares outstanding.
What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?
Adial Pharmaceuticals Inc reported an EPS of -$11.25 in its last earnings report, missing expectations of -$1.032. Following the earnings report the stock price went up 25.377%.
Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ADIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
ADIL Stock 12 Month Forecast
Average Price Target
$11.00
▲(85.19% Upside)
Technical Analysis
―
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Alzamend Neuro
―
Calidi Biotherapeutics
―
Ownership Overview
30.11% Insiders
0.24% Mutual Funds
28.84% Other Institutional Investors
40.58% Public Companies and
Individual Investors